Hologic (HOLX) Expected to Announce Earnings on Thursday

Hologic (NASDAQ:HOLX) is expected to announce its Q1 2026 results after the market closes on Thursday, January 29th. Analysts expect Hologic to post earnings of $1.09 per share and revenue of $1.0734 billion for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 4:30 PM ET.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.03. The firm had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.03 billion. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.01 EPS. On average, analysts expect Hologic to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Hologic Stock Performance

Shares of HOLX opened at $75.14 on Thursday. The company has a current ratio of 3.75, a quick ratio of 3.06 and a debt-to-equity ratio of 0.50. The firm’s fifty day simple moving average is $74.76 and its two-hundred day simple moving average is $70.42. Hologic has a 12 month low of $51.90 and a 12 month high of $75.34. The stock has a market capitalization of $16.75 billion, a P/E ratio of 30.30, a price-to-earnings-growth ratio of 2.13 and a beta of 0.69.

Institutional Investors Weigh In On Hologic

Several large investors have recently modified their holdings of HOLX. Bank of America Corp DE boosted its holdings in shares of Hologic by 2.2% in the second quarter. Bank of America Corp DE now owns 3,090,306 shares of the medical equipment provider’s stock worth $201,364,000 after acquiring an additional 66,453 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in Hologic by 5.4% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,917,418 shares of the medical equipment provider’s stock worth $196,897,000 after purchasing an additional 149,605 shares in the last quarter. Legal & General Group Plc boosted its stake in Hologic by 1.5% in the 3rd quarter. Legal & General Group Plc now owns 1,893,856 shares of the medical equipment provider’s stock worth $127,816,000 after purchasing an additional 28,516 shares during the period. Sei Investments Co. boosted its stake in Hologic by 5.6% in the 3rd quarter. Sei Investments Co. now owns 1,456,904 shares of the medical equipment provider’s stock worth $98,325,000 after purchasing an additional 77,428 shares during the period. Finally, Balyasny Asset Management L.P. grew its holdings in Hologic by 1,060.1% during the 3rd quarter. Balyasny Asset Management L.P. now owns 1,218,352 shares of the medical equipment provider’s stock valued at $82,227,000 after buying an additional 1,113,330 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on HOLX. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a research report on Tuesday, November 4th. Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a research note on Friday, October 31st. BTIG Research reaffirmed a “neutral” rating on shares of Hologic in a research report on Tuesday, October 21st. Raymond James Financial lowered Hologic from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Finally, Wall Street Zen cut Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Three investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to MarketBeat.com, Hologic has an average rating of “Hold” and a consensus price target of $79.31.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.